High-density lipoprotein cholesterol in HIV-infected patients: Evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition

AIDS Patient Care and STDs

Volumn 22, Issue 7, 2008, Pages 569-575

  Bernal, Enrique ^a,b   Masiá, Mar ^a   Padilla, Sergio ^a   Gutiérrez, Félix ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b Hospital General   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; SPAIN; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HOSPITALS, UNIVERSITY; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SPAIN; TRIGLYCERIDES; VIRAL LOAD;

EID: 47849123028     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0186     Document Type: Article

References (34)

1. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
2. Masia-Canuto M, Bernal-Morell E, Gutierrez-Rodero F. Lipid alterations and cardiovascular risk associated with antiretroviral therapy. Enferm Infecc Microbiol Clin 2006;24: 637-648.
3. Masia M, Bernal E, Padilla S, et al. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2007;195:167-171.
4. Bernal E, Masia M, Padilla S, Ramos JM, Martin-Hidalgo A, Gutierrez F. Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir. Med Clin (Barc) 2007;129:252-254.
5. Ridler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-2982.
6. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals - Focus on protease inhibitor therapy. AIDS 2001;15:329-334.
7. Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir- containing regimens. J Acquir Immune Defic Syndr 2003;33:594-600.
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
9. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000;86: 19L-22L.
10. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov D. HIV infection and high-density lipoprotein: The effect of the disease vs the effect of treatment. Metabolism 2006;55:90-95.
11. van d, V, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;1518: 2407-2414.
12. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002;16:1383-1389.
13. Balkau B, Vernay M, Mhamdi L, et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab 2003;29:526-532.
14. Marques-Vidal P, Mazoyer E, Bongard V, et al. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002;25:1371-1377.
15. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB, Sr., Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003;52:2160-2167.
16. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995;75:1196-1201.
17. Sanchez-Chaparro MA, Roman-Garcia J, Calvo-Bonacho E, et al. Prevalence of cardiovascular risk factors in the Spanish working population. Rev Esp Cardiol 2006;59:421-430.
18. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006;43:458-466.
19. Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors. Diabetes Care 2005;28:132-137.
20. Knobel H, Jerico C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: Concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 2007;21:452-457.
21. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naive cohort. HIV Med 2005;6:114-121.
22. Alonso-Villaverde C, Segues T, Coll-Crespo B, et al. High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy. AIDS 2003;17:1173-1178.
23. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007;45:34-42.
24. Tebas P, Henry K, Matinning R. Antiretroviral treatment interruption, immune activation and cardiovascular risk. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: 2007.
25. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
26. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167:73-79.
27. Masia M, Padilla S, Bernal E, et al. Influence of antirretroviral therapy on oxidative stress and cardiovascular risk: A prospective cross-sectional study in HIV-infected patients. Clin Ther 2007;29:1448-1455.
28. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005;19:917-925.
29. van LF, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1:e19.
30. Fontas E, van LF, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-1074.
31. Avogaro P, Ghiselli G, Soldan S, Bittolo BG. Relationship of triglycerides and HDL cholesterol in hypertriglyceridemia. Atherosclerosis 1992;92:79-86.
32. Patsch JR. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis 1994;110(Suppl):S23-S26.
33. Polgreen PM, Fultz SL, Justice AC, et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med 2004;5:144-150.
34. D'Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 1998;33:1213-1218.